<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153200</url>
  </required_header>
  <id_info>
    <org_study_id>20210654-01H</org_study_id>
    <nct_id>NCT05153200</nct_id>
  </id_info>
  <brief_title>Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.</brief_title>
  <official_title>Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 4 pilot study is to assess 1-year recruitment, and 6-month&#xD;
      retention rates for participants with rheumatoid arthritis (RA) recruited to this study.&#xD;
      Secondarily, we aim to study the difference in multifaceted pain scoring and Musculoskeletal&#xD;
      Ultrasound (MSK-US)-detected synovitis between those treated with Upadacitinib vs Adalimumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 26-week phase 4 randomized, single-blind, parallel-group, active&#xD;
      treatment-controlled pilot/feasibility study designed to primary assess recruitment and&#xD;
      retention rates and to secondarily assess the efficacy of Upadacitinib vs Adalimumab in&#xD;
      controlling multiple measures of pain and MSK-US-detected synovitis in those with Active&#xD;
      Rheumatoid Arthritis.&#xD;
&#xD;
      Participants with active RA despite combination conventional synthetic Disease Modifying&#xD;
      Antirheumatic Drugs (csDMARD), alternative biologic DMARD (bDMARD), or alternative targeted&#xD;
      synthetic DMARD (tsDMARD) will be randomized in a 1:1 ratio to:&#xD;
&#xD;
        -  Upadacitinib(Rinvoq) 15 mg orally (po) daily or&#xD;
&#xD;
        -  Comparison Group: Adalimumab(Idacio) 40 mg subcutaneously (sc) every other week Baseline&#xD;
           methotrexate may be continued if patient is receiving at time of study enrollment.&#xD;
&#xD;
      At 1 year after study initiation, recruitment rate over the first year will be measured and&#xD;
      rate of 6-month participant retention will also be measured.&#xD;
&#xD;
      At baseline, 1 month, 3 months, and 6 months after initiation of study drug, disease&#xD;
      activity, pain, MSK-US synovitis, and other patient important outcomes will be collected.&#xD;
&#xD;
      The study will be completed after 6-months of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>MSK-US assessors will be blinded to treatment allocation, pain scores, and disease activity measures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants recruited to study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of participants who complete the 6 months of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 100 mm Pain visual analogue scale (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>&quot;no pain&quot; and &quot;pain as bad as it can be&quot; as anchors (MCID=11 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in McGill Pain Questionnaire (MPQ)</measure>
    <time_frame>6 months</time_frame>
    <description>Detailed assessment of pain quantity, quality, and impact (MCID=5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Widespread Pain Index (WPI)</measure>
    <time_frame>6 months</time_frame>
    <description>Score of 4 or more indicates widespread pain (no known MCID)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PainDETECT Questionnaire (PDQ)</measure>
    <time_frame>6 months</time_frame>
    <description>Nociceptive (PDQ&lt;13, unclear pain PDQ 14-18, neuropathic pain &gt;18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OMERACT (Outcome Measures in Rheumatoid Arthritis in Clinical Trials) ultrasound task force Global Synovitis Score (GLOESS).</measure>
    <time_frame>6 months</time_frame>
    <description>US assessment of 32 joints assessing for Gray-scale synovitis and power-Doppler findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count (44)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tender Joint Count (44)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Global Assessment of Disease Severity</measure>
    <time_frame>6 months</time_frame>
    <description>VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Assessment of Disease Severity</measure>
    <time_frame>6 months</time_frame>
    <description>VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 20 response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50 response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70 response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erythrocyte Sedimentation Rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-Reactive Protein</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS)-28-ESR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS-28-CRP</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index (ISI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form 36 (SF-36)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop-out due to Adverse Events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Upadacitinib(Rinvoq)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upadacitinib(Rinvoq) 15 mg po daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab(Idacio)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>15 mg po daily</description>
    <arm_group_label>Upadacitinib(Rinvoq)</arm_group_label>
    <other_name>Rinvoq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>40 mg sc every other week</description>
    <arm_group_label>Adalimumab(Idacio)</arm_group_label>
    <other_name>Idacio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of RA based on ACR/EULAR 2020 Classification Criteria&#xD;
&#xD;
          -  Moderate-to-high disease activity according to clinical disease activity indices&#xD;
&#xD;
          -  Referred to the biologics clinic (The Ottawa Hospital Arthritis Centre) by their&#xD;
             primary rheumatologist who practices within the division following decision to&#xD;
             escalate to, or switch between, advanced therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to initiation of either Upadacitinib or Adalimumab&#xD;
&#xD;
          -  Unable to come to follow-up at 1, 3, and 6 months&#xD;
&#xD;
          -  Current or planned (within 6 months) pregnancy or breastfeeding&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Inability to communicate verbal or written responses to pain questionnaires&#xD;
&#xD;
          -  Intraarticular steroid injections if done within 30 days of first visit&#xD;
&#xD;
          -  Initiation of study intervention prior to baseline assessment&#xD;
&#xD;
          -  Previous use of either study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elliot P Hepworth, MD</last_name>
    <phone>613-738-8400</phone>
    <phone_ext>81571</phone_ext>
    <email>elhepworth@toh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sibel Z Aydin, MD</last_name>
    <phone>(613) 738-8400</phone>
    <phone_ext>81840</phone_ext>
    <email>saydin@toh.ca</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Synovitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

